Metabolic Syndrome
3 competing products in clinical development for Metabolic Syndrome.
Pipeline by Phase
Phase 32
Approved1
All Products (3)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + Amlodipine | Daiichi Sankyo | Phase 3 | Completed | 40 |
| olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomil | Daiichi Sankyo | Phase 3 | Completed | 40 |
| Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mg | Yuhan | Approved | Terminated | 35 |